Published
{
"ticker": "AZN",
"cik": "0000901832",
"company": "AstraZeneca PLC",
"business_type": "pharmaceutical",
"schema_template": "standard (industrial/pharma): revenue split into Product Sales, Alliance Revenue and Collaboration Revenue as AstraZeneca presents it; IFRS line names",
"reporting_currency": "USD",
"converted_to_usd": false,
"units": "actual US dollars (not millions); per-share figures in US dollars per ordinary share; share counts in actual shares",
"units_notes_seen": {
"FY2025 20-F Consolidated Statement of Comprehensive Income (for the year ended 31 December)": "column heads '$m' over 2025 | 2024 | 2023; footnote '$m means millions of US dollars.'; earnings per $0.25 Ordinary Share printed in dollars; share counts labelled '(millions)'",
"FY2025 20-F Consolidated Statement of Financial Position (at 31 December)": "column heads '$m' over 2025 | 2024 (millions of US dollars)",
"FY2025 20-F Consolidated Statements of Cash Flows (for the year ended 31 December)": "column heads '$m' over 2025 | 2024 | 2023 (millions of US dollars); outflows in brackets",
"H1 2026 results 6-K, Table 17 Condensed consolidated statement of comprehensive income: H1 2026": "'For the half year ended 30 June', column heads '$m' over 2026 | 2025; EPS printed in dollars; share counts labelled '(millions)'",
"H1 2026 results 6-K, Table 18 Condensed consolidated statement of comprehensive income: Q2 2026": "'For the quarter ended 30 June', 'Unreviewed', column heads '$m' over 2026 | 2025; EPS printed in dollars; share counts labelled '(millions)'",
"H1 2026 results 6-K, Table 19 Condensed consolidated statement of financial position": "column heads 'Reviewed At 30 Jun 2026 | Audited At 31 Dec 2025 | Reviewed At 30 Jun 2025', each '$m'",
"H1 2026 results 6-K, Table 21 Condensed consolidated statement of cash flows: H1 2026": "'For the half year ended 30 June', column heads '$m' over 2026 | 2025",
"H1 2026 results 6-K, Tables 10, 11 and 13 (Core reconciliations, Net debt summary)": "column heads '$m'; EPS rows in dollars"
},
"adjustments": {
"splits_applied": [],
"adr_ratio": null,
"fx": "none: AstraZeneca presents its consolidated statements in US dollars, its functional currency",
"per_share_basis": "per Ordinary Share of $0.25 nominal value. AstraZeneca terminated its American Depositary Receipt programme and listed its Ordinary Shares directly on the New York Stock Exchange effective 2 February 2026, so a US holder now owns Ordinary Shares and no ADS conversion applies.",
"sign_convention": "income statement expense lines (cost of sales, distribution, R&D, SG&A, finance expense, share of associate and joint venture losses, taxation) are stored as positive amounts; other operating income and expense is net income (positive) or net expense (negative); balance sheet liabilities, borrowings and net debt are stored as positive amounts; cash flow lines keep the statement's sign (outflows negative)."
},
"annual": [
{
"fiscal_year": 2025,
"label": "FY2025",
"period_start": "2025-01-01",
"period_end": "2025-12-31",
"period_type": "fiscal year",
"source_accession": "0001104659-26-019130",
"income_statement": {
"product_sales": 55573000000,
"alliance_revenue": 3067000000,
"product_revenue": 58640000000,
"collaboration_revenue": 99000000,
"total_revenue": 58739000000,
"cost_of_sales": 10633000000,
"gross_profit": 48106000000,
"distribution_expense": 579000000,
"research_and_development_expense": 14232000000,
"selling_general_and_administrative_expense": 19933000000,
"other_operating_income_and_expense": 381000000,
"operating_profit": 13743000000,
"finance_income": 360000000,
"finance_expense": 1694000000,
"share_of_losses_of_associates_and_joint_ventures": 7000000,
"profit_before_tax": 12402000000,
"taxation": 2169000000,
"net_income": 10233000000,
"net_income_attributable_to_owners_of_parent": 10225000000,
"net_income_attributable_to_noncontrolling_interests": 8000000,
"basic_eps": 6.6,
"diluted_eps": 6.54,
"basic_shares": 1550000000,
"diluted_shares": 1562000000
},
"balance_sheet": {
"property_plant_and_equipment": 12962000000,
"goodwill": 21242000000,
"intangible_assets": 37846000000,
"total_non_current_assets": 85351000000,
"inventories": 6557000000,
"trade_and_other_receivables": 15177000000,
"cash_and_cash_equivalents": 5711000000,
"total_current_assets": 28723000000,
"total_assets": 114074000000,
"current_interest_bearing_loans_and_borrowings": 3104000000,
"current_lease_liabilities": 382000000,
"trade_and_other_payables": 25280000000,
"total_current_liabilities": 30617000000,
"non_current_interest_bearing_loans_and_borrowings": 24715000000,
"non_current_lease_liabilities": 1421000000,
"total_non_current_liabilities": 34738000000,
"total_liabilities": 65355000000,
"equity_attributable_to_owners_of_parent": 48667000000,
"noncontrolling_interests": 52000000,
"total_equity": 48719000000,
"total_debt": 27819000000
},
"cash_flow": {
"depreciation_amortisation_and_impairment": 5733000000,
"operating_cash_flow": 14575000000,
"acquisition_of_subsidiaries_net_of_cash_acquired": -66000000,
"capex": -2810000000,
"purchase_of_intangible_assets": -3095000000,
"investing_cash_flow": -6808000000,
"dividends_paid": -4971000000,
"financing_cash_flow": -7544000000,
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": 5698000000,
"free_cash_flow": 11765000000
}
},
{
"fiscal_year": 2024,
"label": "FY2024",
"period_start": "2024-01-01",
"period_end": "2024-12-31",
"period_type": "fiscal year",
"source_accession": "0001104659-26-019130",
"income_statement": {
"product_sales": 50938000000,
"alliance_revenue": 2212000000,
"product_revenue": 53150000000,
"collaboration_revenue": 923000000,
"total_revenue": 54073000000,
"cost_of_sales": 10207000000,
"gross_profit": 43866000000,
"distribution_expense": 555000000,
"research_and_development_expense": 13583000000,
"selling_general_and_administrative_expense": 19977000000,
"other_operating_income_and_expense": 252000000,
"operating_profit": 10003000000,
"finance_income": 458000000,
"finance_expense": 1742000000,
"share_of_losses_of_associates_and_joint_ventures": 28000000,
"profit_before_tax": 8691000000,
"taxation": 1650000000,
"net_income": 7041000000,
"net_income_attributable_to_owners_of_parent": 7035000000,
"net_income_attributable_to_noncontrolling_interests": 6000000,
"basic_eps": 4.54,
"diluted_eps": 4.5,
"basic_shares": 1550000000,
"diluted_shares": 1563000000
},
"balance_sheet": {
"property_plant_and_equipment": 10252000000,
"goodwill": 21025000000,
"intangible_assets": 37177000000,
"total_non_current_assets": 78208000000,
"inventories": 5288000000,
"trade_and_other_receivables": 12972000000,
"cash_and_cash_equivalents": 5488000000,
"total_current_assets": 25827000000,
"total_assets": 104035000000,
"current_interest_bearing_loans_and_borrowings": 2337000000,
"current_lease_liabilities": 339000000,
"trade_and_other_payables": 22465000000,
"total_current_liabilities": 27866000000,
"non_current_interest_bearing_loans_and_borrowings": 26506000000,
"non_current_lease_liabilities": 1113000000,
"total_non_current_liabilities": 35298000000,
"total_liabilities": 63164000000,
"equity_attributable_to_owners_of_parent": 40786000000,
"noncontrolling_interests": 85000000,
"total_equity": 40871000000,
"total_debt": 28843000000
},
"cash_flow": {
"depreciation_amortisation_and_impairment": 6688000000,
"operating_cash_flow": 11861000000,
"acquisition_of_subsidiaries_net_of_cash_acquired": -2771000000,
"capex": -1924000000,
"purchase_of_intangible_assets": -2662000000,
"investing_cash_flow": -7980000000,
"dividends_paid": -4629000000,
"financing_cash_flow": -3996000000,
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": 5429000000,
"free_cash_flow": 9937000000
}
},
{
"fiscal_year": 2023,
"label": "FY2023",
"period_start": "2023-01-01",
"period_end": "2023-12-31",
"period_type": "fiscal year",
"source_accession": "0001104659-26-019130",
"income_statement": {
"product_sales": 43789000000,
"alliance_revenue": 1428000000,
"product_revenue": 45217000000,
"collaboration_revenue": 594000000,
"total_revenue": 45811000000,
"cost_of_sales": 8268000000,
"gross_profit": 37543000000,
"distribution_expense": 539000000,
"research_and_development_expense": 10935000000,
"selling_general_and_administrative_expense": 19216000000,
"other_operating_income_and_expense": 1340000000,
"operating_profit": 8193000000,
"finance_income": 344000000,
"finance_expense": 1626000000,
"share_of_losses_of_associates_and_joint_ventures": 12000000,
"profit_before_tax": 6899000000,
"taxation": 938000000,
"net_income": 5961000000,
"net_income_attributable_to_owners_of_parent": 5955000000,
"net_income_attributable_to_noncontrolling_interests": 6000000,
"basic_eps": 3.84,
"diluted_eps": 3.81,
"basic_shares": 1549000000,
"diluted_shares": 1562000000
},
"cash_flow": {
"depreciation_amortisation_and_impairment": 5387000000,
"operating_cash_flow": 10345000000,
"acquisition_of_subsidiaries_net_of_cash_acquired": -189000000,
"capex": -1361000000,
"purchase_of_intangible_assets": -2417000000,
"investing_cash_flow": -4064000000,
"dividends_paid": -4481000000,
"financing_cash_flow": -6567000000,
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": 5637000000,
"free_cash_flow": 8984000000
}
}
],
"quarterly": [
{
"label": "Q2 2026",
"period_start": "2026-04-01",
"period_end": "2026-06-30",
"period_type": "three months",
"source_accession": "0001104659-26-086846",
"income_statement": {
"product_sales": 14510000000,
"alliance_revenue": 874000000,
"product_revenue": 15384000000,
"total_revenue": 15384000000,
"cost_of_sales": 2523000000,
"gross_profit": 12861000000,
"distribution_expense": 145000000,
"research_and_development_expense": 4053000000,
"selling_general_and_administrative_expense": 5651000000,
"other_operating_income_and_expense": 152000000,
"operating_profit": 3164000000,
"finance_income": 80000000,
"finance_expense": 435000000,
"share_of_losses_of_associates_and_joint_ventures": 10000000,
"profit_before_tax": 2799000000,
"taxation": 291000000,
"net_income": 2508000000,
"net_income_attributable_to_owners_of_parent": 2507000000,
"net_income_attributable_to_noncontrolling_interests": 1000000,
"basic_eps": 1.61,
"diluted_eps": 1.61,
"basic_shares": 1551000000,
"diluted_shares": 1560000000,
"collaboration_revenue": 0
},
"balance_sheet": {
"property_plant_and_equipment": 13615000000,
"goodwill": 21181000000,
"intangible_assets": 37723000000,
"total_non_current_assets": 87868000000,
"inventories": 6932000000,
"trade_and_other_receivables": 14330000000,
"cash_and_cash_equivalents": 4893000000,
"total_current_assets": 27965000000,
"total_assets": 115833000000,
"current_interest_bearing_loans_and_borrowings": 5808000000,
"current_lease_liabilities": 426000000,
"trade_and_other_payables": 22893000000,
"total_current_liabilities": 31553000000,
"non_current_interest_bearing_loans_and_borrowings": 23683000000,
"non_current_lease_liabilities": 2322000000,
"total_non_current_liabilities": 33910000000,
"total_liabilities": 65463000000,
"equity_attributable_to_owners_of_parent": 50295000000,
"noncontrolling_interests": 75000000,
"total_equity": 50370000000,
"net_debt": 26912000000,
"total_debt": 29491000000
},
"non_gaap": {
"core_operating_profit": 5158000000,
"core_eps": 2.63
}
},
{
"label": "Q2 2025",
"period_start": "2025-04-01",
"period_end": "2025-06-30",
"period_type": "three months",
"source_accession": "0001104659-26-086846",
"income_statement": {
"product_sales": 13795000000,
"alliance_revenue": 654000000,
"product_revenue": 14449000000,
"collaboration_revenue": 8000000,
"total_revenue": 14457000000,
"cost_of_sales": 2473000000,
"gross_profit": 11984000000,
"distribution_expense": 143000000,
"research_and_development_expense": 3548000000,
"selling_general_and_administrative_expense": 4864000000,
"other_operating_income_and_expense": 79000000,
"operating_profit": 3508000000,
"finance_income": 68000000,
"finance_expense": 439000000,
"share_of_losses_of_associates_and_joint_ventures": 10000000,
"profit_before_tax": 3127000000,
"taxation": 679000000,
"net_income": 2448000000,
"net_income_attributable_to_owners_of_parent": 2450000000,
"net_income_attributable_to_noncontrolling_interests": -2000000,
"basic_eps": 1.58,
"diluted_eps": 1.57,
"basic_shares": 1550000000,
"diluted_shares": 1559000000
},
"balance_sheet": {
"property_plant_and_equipment": 11637000000,
"goodwill": 21222000000,
"intangible_assets": 37925000000,
"total_non_current_assets": 83483000000,
"inventories": 6467000000,
"trade_and_other_receivables": 14168000000,
"cash_and_cash_equivalents": 7058000000,
"total_current_assets": 28939000000,
"total_assets": 112422000000,
"current_interest_bearing_loans_and_borrowings": 6492000000,
"current_lease_liabilities": 361000000,
"trade_and_other_payables": 23986000000,
"total_current_liabilities": 33536000000,
"non_current_interest_bearing_loans_and_borrowings": 24714000000,
"non_current_lease_liabilities": 1272000000,
"total_non_current_liabilities": 34076000000,
"total_liabilities": 67612000000,
"equity_attributable_to_owners_of_parent": 44719000000,
"noncontrolling_interests": 91000000,
"total_equity": 44810000000,
"net_debt": 25227000000,
"total_debt": 31206000000
}
}
],
"year_to_date": {
"label": "H1 2026",
"period_start": "2026-01-01",
"period_end": "2026-06-30",
"period_type": "six months",
"source_accession": "0001104659-26-086846",
"prior_year_comparative": {
"label": "H1 2025",
"period_start": "2025-01-01",
"period_end": "2025-06-30",
"period_type": "six months",
"source_accession": "0001104659-26-086846",
"income_statement": {
"product_sales": 26670000000,
"alliance_revenue": 1293000000,
"product_revenue": 27963000000,
"collaboration_revenue": 82000000,
"total_revenue": 28045000000,
"cost_of_sales": 4714000000,
"gross_profit": 23331000000,
"distribution_expense": 278000000,
"research_and_development_expense": 6707000000,
"selling_general_and_administrative_expense": 9356000000,
"other_operating_income_and_expense": 192000000,
"operating_profit": 7182000000,
"finance_income": 149000000,
"finance_expense": 785000000,
"share_of_losses_of_associates_and_joint_ventures": 17000000,
"profit_before_tax": 6529000000,
"taxation": 1160000000,
"net_income": 5369000000,
"net_income_attributable_to_owners_of_parent": 5366000000,
"net_income_attributable_to_noncontrolling_interests": 3000000,
"basic_eps": 3.46,
"diluted_eps": 3.44,
"basic_shares": 1550000000,
"diluted_shares": 1560000000
},
"cash_flow": {
"depreciation_amortisation_and_impairment": 2673000000,
"operating_cash_flow": 7099000000,
"capex": -1088000000,
"purchase_of_intangible_assets": -1804000000,
"investing_cash_flow": -3361000000,
"dividends_paid": -3357000000,
"financing_cash_flow": -2189000000,
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": 7032000000,
"free_cash_flow": 6011000000
}
},
"income_statement": {
"product_sales": 28896000000,
"alliance_revenue": 1699000000,
"product_revenue": 30595000000,
"collaboration_revenue": 77000000,
"total_revenue": 30672000000,
"cost_of_sales": 5201000000,
"gross_profit": 25471000000,
"distribution_expense": 286000000,
"research_and_development_expense": 7545000000,
"selling_general_and_administrative_expense": 10571000000,
"other_operating_income_and_expense": 341000000,
"operating_profit": 7410000000,
"finance_income": 153000000,
"finance_expense": 828000000,
"share_of_losses_of_associates_and_joint_ventures": 22000000,
"profit_before_tax": 6713000000,
"taxation": 1124000000,
"net_income": 5589000000,
"net_income_attributable_to_owners_of_parent": 5587000000,
"net_income_attributable_to_noncontrolling_interests": 2000000,
"basic_eps": 3.6,
"diluted_eps": 3.58,
"basic_shares": 1550000000,
"diluted_shares": 1561000000
},
"cash_flow": {
"depreciation_amortisation_and_impairment": 3295000000,
"operating_cash_flow": 6224000000,
"capex": -1310000000,
"purchase_of_intangible_assets": -3333000000,
"investing_cash_flow": -4704000000,
"dividends_paid": -3288000000,
"financing_cash_flow": -2325000000,
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": 4884000000,
"free_cash_flow": 4914000000
},
"non_gaap": {
"core_operating_profit": 10510000000,
"core_eps": 5.21
},
"dividends": {
"interim_dividend_declared_per_share": 1.06
}
},
"trailing_twelve_months": {
"label": "Twelve months ended 30 June 2026",
"period_start": "2025-07-01",
"period_end": "2026-06-30",
"period_type": "trailing twelve months",
"source_accession": "0001104659-26-086846",
"source_accessions": [
"0001104659-26-019130",
"0001104659-26-086846"
],
"income_statement": {
"product_sales": 57799000000,
"alliance_revenue": 3473000000,
"product_revenue": 61272000000,
"collaboration_revenue": 94000000,
"total_revenue": 61366000000,
"cost_of_sales": 11120000000,
"gross_profit": 50246000000,
"distribution_expense": 587000000,
"research_and_development_expense": 15070000000,
"selling_general_and_administrative_expense": 21148000000,
"other_operating_income_and_expense": 530000000,
"operating_profit": 13971000000,
"profit_before_tax": 12586000000,
"taxation": 2133000000,
"net_income": 10453000000,
"net_income_attributable_to_owners_of_parent": 10446000000,
"diluted_eps": 6.68
},
"cash_flow": {
"operating_cash_flow": 13700000000,
"capex": -3032000000,
"purchase_of_intangible_assets": -4624000000,
"dividends_paid": -4902000000,
"free_cash_flow": 10668000000
}
},
"notes": [
"Template: a standard industrial/pharmaceutical layout using AstraZeneca's own IFRS line names. Total Revenue is Product Revenue (Product Sales plus Alliance Revenue) plus Collaboration Revenue, as the company presents it; Operating profit is the IFRS 'Operating profit' line; net_income is 'Profit for the period' and net_income_attributable_to_owners_of_parent is the earnings-per-share numerator.",
"Annual figures for FY2023, FY2024 and FY2025 come from the FY2025 Form 20-F (accession 0001104659-26-019130). The 20-F prints three years of income statement and cash flows and two year-ends of balance sheet, so FY2023 carries no balance sheet.",
"Q2 2026, Q2 2025, H1 2026 and H1 2025 come from the H1 and Q2 2026 results furnished on Form 6-K on 27 July 2026 (accession 0001104659-26-086846). AstraZeneca files no Form 10-Q; its interim statements are furnished on Form 6-K.",
"The quarterly entries carry no cash flow statement: the interim results print cash flows for the half year only (H1 2026 and H1 2025), and no first-quarter 2026 cash flow statement is among the filings for this period, so the second quarter's cash flows cannot be derived. Half-year cash flows are in the year-to-date block.",
"The Q2 2026 and Q2 2025 three-month income statements are labelled 'Unreviewed' in the filing; the half-year statements were reviewed by the auditors under ISRE 2410.",
"Q2 2026 Collaboration Revenue is printed as a dash (nil); Total Revenue equals Product Revenue of $15,384m in that quarter.",
"total_debt is interest-bearing loans and borrowings, current plus non-current, as printed on the statement of financial position; it excludes lease liabilities, which are shown separately. net_debt is AstraZeneca's own non-GAAP measure from its Net debt summary (gross borrowings including leases, net of derivatives, less cash and current investments) and is given for 30 June 2026 and 30 June 2025.",
"capex is 'Purchase of property, plant and equipment'. free_cash_flow is net cash inflow from operating activities less that capex. It does not deduct 'Purchase of intangible assets' (licences, milestones and software), which is shown separately and was $3,333m in H1 2026 against $1,804m in H1 2025, including a $1,104m upfront payment to CSPC Pharmaceuticals. AstraZeneca's own capital expenditure measure, which adds software-related intangibles, was $1,513m in H1 2026 (H1 2025: $1,303m).",
"The trailing twelve months to 30 June 2026 are derived as FY2025 (from the FY2025 Form 20-F (accession 0001104659-26-019130)) plus H1 2026 less H1 2025 (both from the H1 and Q2 2026 results furnished on Form 6-K on 27 July 2026 (accession 0001104659-26-086846)). Its diluted EPS of $6.68 is the same sum applied to the printed per-share figures, not a figure the company reports.",
"non_gaap holds AstraZeneca's Core measures (Core operating profit and Core EPS) from its reconciliation tables (Tables 10 and 11). Core figures exclude restructuring costs, intangible asset amortisation and impairments, and other items the company lists; they are company-defined and not IFRS measures. The filing prints the current-period Core figures and their percentage change, not the prior-year Core amounts.",
"The H1 2026 interim dividend declared is $1.06 per Ordinary Share, announced with the results on 27 July 2026 and paid on 8 September 2026; the company says it intends to increase the FY2026 annual dividend to $3.30 per share.",
"Share data: AstraZeneca did not split or consolidate its shares in these periods; the weighted average share count is about 1,550 million throughout and no per-share figure has been adjusted. On 2 February 2026 its ADR programme ended and its Ordinary Shares began trading directly on the New York Stock Exchange, so every per-share figure here, before and after that date, is per Ordinary Share.",
"The H1 2025 and Q2 2025 comparatives for Total Revenue, profit for the period and diluted EPS are unchanged from those AstraZeneca reported in its H1 2025 results, and the 31 December 2025 balance sheet totals in the interim results (total assets $114,074m, total liabilities $65,355m, total equity $48,719m) are the same as in the FY2025 Form 20-F."
],
"uncertainties": [
"Second-quarter cash flows (operating cash flow, capex, free cash flow) are not available for Q2 2026 or Q2 2025, because the interim results print only half-year cash flows.",
"The trailing-twelve-month diluted EPS ($6.68) is a sum of reported per-share amounts, not earnings divided by a weighted share count, and may differ by a cent or two from a figure computed on a twelve-month share count."
],
"headline": {
"period": "Q2 FY2026",
"period_end_words": "June 30, 2026",
"metrics": [
{
"label": "Revenue",
"format": "usd",
"value": 15384000000,
"text": "$15.38 billion",
"exact": "$15,384,000,000",
"compact": "$15.38B",
"abs": "$15.38 billion",
"prior_value": 14457000000,
"prior": "$14.46 billion",
"priorabs": "$14.46 billion",
"yoy": "up 6.4%",
"source": {
"array": "quarterly",
"field": "income_statement.total_revenue",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001104659-26-086846",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001104659-26-086846",
"gap_days": 365
}
},
{
"label": "Net income",
"format": "usd",
"value": 2507000000,
"text": "$2.51 billion",
"exact": "$2,507,000,000",
"compact": "$2.51B",
"abs": "$2.51 billion",
"prior_value": 2450000000,
"prior": "$2.45 billion",
"priorabs": "$2.45 billion",
"yoy": "up 2.3%",
"source": {
"array": "quarterly",
"field": "income_statement.net_income_attributable_to_owners_of_parent",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001104659-26-086846",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001104659-26-086846",
"gap_days": 365
}
},
{
"label": "Diluted EPS",
"format": "eps",
"value": 1.61,
"text": "$1.61",
"exact": "$1.61",
"compact": "$1.61",
"abs": "$1.61",
"prior_value": 1.57,
"prior": "$1.57",
"priorabs": "$1.57",
"yoy": "up 2.5%",
"source": {
"array": "quarterly",
"field": "income_statement.diluted_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001104659-26-086846",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001104659-26-086846",
"gap_days": 365
}
},
{
"label": "Operating profit",
"format": "usd",
"value": 3164000000,
"text": "$3.16 billion",
"exact": "$3,164,000,000",
"compact": "$3.16B",
"abs": "$3.16 billion",
"prior_value": 3508000000,
"prior": "$3.51 billion",
"priorabs": "$3.51 billion",
"yoy": "down 9.8%",
"source": {
"array": "quarterly",
"field": "income_statement.operating_profit",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001104659-26-086846",
"prior_index": 1,
"prior_period_label": "Q2 2025",
"prior_period_end": "2025-06-30",
"prior_period_start": "2025-04-01",
"prior_span_days": 90,
"prior_source_accession": "0001104659-26-086846",
"gap_days": 365
}
},
{
"label": "Core EPS",
"format": "eps",
"value": 2.63,
"text": "$2.63",
"exact": "$2.63",
"compact": "$2.63",
"abs": "$2.63",
"prior_value": null,
"prior": null,
"priorabs": null,
"yoy": null,
"source": {
"array": "quarterly",
"field": "non_gaap.core_eps",
"index": 0,
"period_label": "Q2 2026",
"period_end": "2026-06-30",
"period_start": "2026-04-01",
"span_days": 90,
"source_accession": "0001104659-26-086846"
}
}
],
"summary": "AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026, up 6.4% from a year earlier, and net income attributable to shareholders of $2.51 billion, up 2.3%, or $1.61 per diluted ordinary share. Operating profit was $3.16 billion, down 9.8%, because of larger charges that AstraZeneca excludes from its Core measures, mainly intangible amortisation and impairments, including write-downs of development-stage intangible assets in research and development, but a lower tax charge more than offset that decline at the net income line. On its Core basis, which also excludes restructuring costs and other listed items, costs grew roughly in line with revenue, Core operating profit rose and AstraZeneca earned $2.63 per share.",
"qa": [
{
"q": "How much revenue did AstraZeneca make in Q2 FY2026?",
"a": "AstraZeneca reported total revenue of $15.38 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 6.4% from $14.46 billion in the same quarter a year earlier."
},
{
"q": "What were AstraZeneca's net income and EPS in Q2 FY2026?",
"a": "AstraZeneca's net income attributable to shareholders was $2.51 billion in Q2 FY2026, up 2.3% from $2.45 billion a year earlier. Diluted earnings per ordinary share were $1.61, against $1.57 in the same quarter a year earlier."
},
{
"q": "Why did AstraZeneca's operating profit fall in Q2 FY2026?",
"a": "AstraZeneca's operating profit was $3.16 billion in Q2 FY2026, down 9.8% from $3.51 billion a year earlier, because of larger charges that AstraZeneca excludes from its Core measures: impairments of development-stage intangible assets in research and development, and intangible amortisation and impairments, restructuring and other listed items in selling, general and administrative costs. On its Core basis, costs grew roughly in line with revenue and Core operating profit rose. Despite the lower reported operating profit, a lower tax charge, which reflected an adjustment to deferred tax assets, meant AstraZeneca's net income still rose to $2.51 billion."
},
{
"q": "What was AstraZeneca's Core EPS in Q2 FY2026?",
"a": "AstraZeneca reported Core earnings per share of $2.63 for Q2 FY2026, the quarter ended June 30, 2026. Core EPS is the company's own measure, not an IFRS figure; it excludes intangible amortisation and impairments, restructuring costs and other items the company lists, and compares with reported diluted EPS of $1.61."
}
]
},
"company_details": {
"Name": "Astrazeneca Plc",
"Ticker": "AZN",
"CIK": "0000901832",
"Exchange": "NYSE",
"State": "",
"Incorporation": "United Kingdom",
"SIC": "2834",
"Office": "Life Sciences",
"Industry": "Pharmaceutical Preparations"
},
"next_filing": {
"predicted_date": "2026-11-05",
"predicted_type": "6-K"
},
"fiscal_period": {
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"form": "6-K",
"accession": "0001104659-26-086846",
"fiscal_year_end": "1231",
"source": "derived"
},
"source_filings": [
{
"role": "annual",
"current": false,
"form": "20-F",
"fiscal_year": 2025,
"fiscal_period": "FY",
"tag": "FY25",
"period_end": "2025-12-31",
"filed": "2026-02-24",
"accession": "0001104659-26-019130",
"url": "https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm",
"source": "reported"
},
{
"role": "quarterly",
"current": true,
"form": "6-K",
"fiscal_year": 2026,
"fiscal_period": "Q2",
"tag": "FY26Q2",
"period_end": "2026-06-30",
"filed": "2026-07-27",
"accession": "0001104659-26-086846",
"url": "https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/0001104659-26-086846-index.htm",
"source": "derived"
}
],
"figure_sources": {
"about": "Where each figure in this file is printed in its SEC filing. This block mirrors the paths of the figures: figure_sources.annual[0].income_statement.net_income is the source of annual[0].income_statement.net_income. Each entry reads '<document>#<anchor>', and the link is documents[<document>] + '#<anchor>': it opens the filing at the line that prints that number. A figure with no entry is not printed in a tagged filing, either because it was calculated (margins, free cash flow, trailing twelve months, a quarter derived by subtraction) or because it comes from an untagged earnings release.",
"documents": {
"d1": "https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm"
},
"annual": [
{
"period_end": "2025-12-31",
"income_statement": {
"product_sales": "d1#Tc_gGSICMxzsEGb5PweB0pWAg_3_4",
"alliance_revenue": "d1#Tc_J9bg5Nz6wUKSLPNskug1NQ_4_4",
"product_revenue": "d1#Tc_5bhDqygzfUC_DRcMBcnw1w_5_4",
"collaboration_revenue": "d1#Tc_-haDIAf_vEK5GjBQG4C24g_6_4",
"total_revenue": "d1#Tc_KbtzzmG57UuOn4sFF-CJhA_7_4",
"cost_of_sales": "d1#Tc_3K4ceuer8UKrqrRjE9qP5w_8_4",
"gross_profit": "d1#Tc_LQ0BYs_PVU-__cQFxR0Qjw_9_4",
"distribution_expense": "d1#Tc_9xzzyc7CZkqJi6SOj0aHJg_10_4",
"research_and_development_expense": "d1#Tc_DzXR-_uR-0yerlbetjYEgA_11_4",
"selling_general_and_administrative_expense": "d1#Tc_ZPuH3cPm0E6v0E0j6f28fA_12_4",
"other_operating_income_and_expense": "d1#Tc_8EJJR86Wi0iL7iWP1462ow_13_4",
"operating_profit": "d1#Tc_AH-3wn4dA0OOP-V6kZpnDA_14_4",
"finance_income": "d1#Tc_8pWl5G-XbUaw_IpA5-k03A_15_4",
"finance_expense": "d1#Tc_du5jKcJEgkmn4rorM7aD1A_16_4",
"share_of_losses_of_associates_and_joint_ventures": "d1#Tc__1N-dVs60U61Bz1FWqQ3zw_17_4",
"profit_before_tax": "d1#Tc_4zoKE-jzrk-xAvUEOJZY1A_18_4",
"taxation": "d1#Tc_Nxxvd7bxxkW3YMS1RxGHuQ_19_4",
"net_income": "d1#Tc_PZRoO-tolU60BaBZuzC7HQ_20_4",
"net_income_attributable_to_owners_of_parent": "d1#Tc_K6QUH5CPoEyyAWHLrlIe-g_41_4",
"net_income_attributable_to_noncontrolling_interests": "d1#Tc_N8O4yv_NGkS-iIZZUPWy2g_42_4",
"basic_eps": "d1#Tc_HFXvaBo8nEKpJS0bWJg1wQ_47_4",
"diluted_eps": "d1#Tc_lX7kRSvXmEGyM67fVs_GLQ_48_4",
"basic_shares": "d1#Tc_AOiY1bnxC0KGEBHQyFXabQ_49_4",
"diluted_shares": "d1#Tc_AxX_f6SbQEuFBZfto-sxvw_50_4"
},
"balance_sheet": {
"property_plant_and_equipment": "d1#Tc_DfgeIPCLPk--nIUZKM7drQ_5_4",
"goodwill": "d1#Tc_SueCwLJCc06WCVCENiOGWg_7_4",
"intangible_assets": "d1#Tc_nIk2CGfxXk6M9S0H6CqT6A_8_4",
"total_non_current_assets": "d1#Tc_gjkZudPCtESDq9jNrZoa4w_15_4",
"inventories": "d1#Tc_Phn556OLI0OqNNq5lPW7tA_17_4",
"trade_and_other_receivables": "d1#Tc_nA0LqgwlxUKLRndsj8tUSw_18_4",
"cash_and_cash_equivalents": "d1#Tc_rrHDBLOY20-Vj_J3xq2iLA_22_4",
"total_current_assets": "d1#Tc_UP2pL71lhUy-eXKVBDEbSQ_23_4",
"total_assets": "d1#Tc_bloB9PSiFUaMlZldgqR4Ew_24_4",
"current_interest_bearing_loans_and_borrowings": "d1#Tc_SQLhA23UAEStUTB03_lA4w_27_4",
"current_lease_liabilities": "d1#Tc_oKdqXv_VcEuy4hh6C4l40w_28_4",
"trade_and_other_payables": "d1#Tc_qQ9HvZgXlkOJ0hv08jDcFQ_29_4",
"total_current_liabilities": "d1#Tc_3PmKH2dKGUm9HP2Z7UVDQg_33_4",
"non_current_interest_bearing_loans_and_borrowings": "d1#Tc_UbpNH1jLe0OgudcM1hDEyg_35_4",
"non_current_lease_liabilities": "d1#Tc_e4wzoOQ1MEqEB7-PewNiUQ_36_4",
"total_non_current_liabilities": "d1#Tc_su83Rv3WmkaexIkI1stSow_43_4",
"total_liabilities": "d1#Tc_0lKFX1Lcf0aFuLTQtUSJ6Q_44_4",
"equity_attributable_to_owners_of_parent": "d1#Tc_uQf0ufxP2kire5gZjkeneA_54_4",
"noncontrolling_interests": "d1#Tc_6RCRaPTQ-EiRvxAoftO5XQ_55_4",
"total_equity": "d1#Tc_So_laj5wJkWZtxG5NHyJCQ_56_4"
},
"cash_flow": {
"depreciation_amortisation_and_impairment": "d1#Tc_xUQGQng2YUeMiZAuXoKYvQ_7_4",
"operating_cash_flow": "d1#Tc_8eDRD2go-0OtH4-4lhFh4Q_17_4",
"capex": "d1#Tc_r1IOb0ITOk-syZVD640mlA_22_4",
"purchase_of_intangible_assets": "d1#Tc_Or59_jqYPECaiT_tgOxihQ_24_4",
"investing_cash_flow": "d1#Tc_i4_w7DjkW0yXUJTE9nPCcQ_33_4",
"dividends_paid": "d1#Tc_RCLu_Y4qpU2RSWfQfmf3dQ_41_4",
"financing_cash_flow": "d1#Tc_7TwJPkgi5kGiUDXiksmakw_46_4",
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": "d1#Tc_ZdSvwnsUdEONuqUgi0DX2A_50_4"
}
},
{
"period_end": "2024-12-31",
"income_statement": {
"product_sales": "d1#Tc_RqcN4L9Bg0m79CLOhFBjnw_3_6",
"alliance_revenue": "d1#Tc_obd1UMQh70ynvG5TFW-N6Q_4_6",
"product_revenue": "d1#Tc_PA5lIsc1yk6G_MI2MacGYw_5_6",
"collaboration_revenue": "d1#Tc_-HsC-3k9hUuWSZ9Q-IIzaw_6_6",
"total_revenue": "d1#Tc_vzYjS_AyiUa3euIcFzPQ9Q_7_6",
"cost_of_sales": "d1#Tc_tDpkE8IG_Eeka5UfIXsutg_8_6",
"gross_profit": "d1#Tc_vdAstzj800urarjZGr3UeQ_9_6",
"distribution_expense": "d1#Tc_rFjZwnTaP0ytO6e3PhRe1Q_10_6",
"research_and_development_expense": "d1#Tc_0auumfvqPEuIodRZj_LLng_11_6",
"selling_general_and_administrative_expense": "d1#Tc_aBsnmO9Zj02R_TT975UlCw_12_6",
"other_operating_income_and_expense": "d1#Tc_TSLFxrmUtEqrIgEFsn1-4Q_13_6",
"operating_profit": "d1#Tc_Ovy5_6vWrUG_gyixoUuonQ_14_6",
"finance_income": "d1#Tc_okLtOvhC-E2YDc9C4QyxUA_15_6",
"finance_expense": "d1#Tc_wapqpWM0DU6bWl_XmSqgmg_16_6",
"share_of_losses_of_associates_and_joint_ventures": "d1#Tc_Jo36lIaBZ0-mnTEmY849QQ_17_6",
"profit_before_tax": "d1#Tc_efHglcDk8Eu1Bd7n23oBIQ_18_6",
"taxation": "d1#Tc_Ktw-DOZ-S0e78JT3Qk4v3Q_19_6",
"net_income": "d1#Tc_oPHxxKDWwk-ZHgOybQID4A_20_6",
"net_income_attributable_to_owners_of_parent": "d1#Tc_X75-GUXpKU6SRIbU-oWt3Q_41_6",
"net_income_attributable_to_noncontrolling_interests": "d1#Tc_QNp9mFhCbkKnNscU1qyIjQ_42_6",
"basic_eps": "d1#Tc_G5TrIeL3pke1ESheYsui_g_47_6",
"diluted_eps": "d1#Tc_aSRQ3FtTvEGi5u7Ro4UpDA_48_6",
"basic_shares": "d1#Tc__7C0etdkJUO6Mnd4iB9Tgw_49_6",
"diluted_shares": "d1#Tc_rzcD673lL0-2Z5urQJuj_g_50_6"
},
"balance_sheet": {
"property_plant_and_equipment": "d1#Tc_si5UKV_qPkWnSK2x3Cfz6w_5_6",
"goodwill": "d1#Tc_7ZETnlRPm0OMYV7VlfB29Q_7_6",
"intangible_assets": "d1#Tc_tBoq2rCIAUORDQ6Ytg8dag_8_6",
"total_non_current_assets": "d1#Tc_t0_B0HD7ckWeyShefLSfDA_15_6",
"inventories": "d1#Tc_xOj085s5N0mjhdDQtCbobg_17_6",
"trade_and_other_receivables": "d1#Tc_8QxqxQAz-UWi9hKtxD20jA_18_6",
"cash_and_cash_equivalents": "d1#Tc_V06WwW7nvEG9BLx6c78kHQ_22_6",
"total_current_assets": "d1#Tc_XF1hFd3-iUqv1FxUcQmDsw_23_6",
"total_assets": "d1#Tc_Jp8kVEPd70u0fykQuFEfLw_24_6",
"current_interest_bearing_loans_and_borrowings": "d1#Tc_wNJWWYYxfk6NrRCaZytsdQ_27_6",
"current_lease_liabilities": "d1#Tc_tgaWht9UJ0SjwSP-vNHlAg_28_6",
"trade_and_other_payables": "d1#Tc_S_YkiBVq2EeT6hPugphSlg_29_6",
"total_current_liabilities": "d1#Tc_9EmIwWNBnEur4Tz4yDJM7g_33_6",
"non_current_interest_bearing_loans_and_borrowings": "d1#Tc_ntfzhEtNmUad4d84dLPAnQ_35_6",
"non_current_lease_liabilities": "d1#Tc_2gwzY0BGN0GgZxc_O1y-WA_36_6",
"total_non_current_liabilities": "d1#Tc_VMBevNNpU06qyQO3udYGjg_43_6",
"total_liabilities": "d1#Tc_k5-xKuvL7EKDAhc7i_fv-Q_44_6",
"equity_attributable_to_owners_of_parent": "d1#Tc_4DEpnt2860iEA7G4VCPY6Q_54_6",
"noncontrolling_interests": "d1#Tc_W9XJZq1pJ0iW9W9K0Ch6cA_55_6",
"total_equity": "d1#Tc_UkMkc84XyUOJrc0xAXSK-g_56_6"
},
"cash_flow": {
"depreciation_amortisation_and_impairment": "d1#Tc_MySRdo5FzUOxFJxeGr_t-Q_7_6",
"operating_cash_flow": "d1#Tc_uP0zj-wSy066l8urEi1BDQ_17_6",
"acquisition_of_subsidiaries_net_of_cash_acquired": "d1#Tc_jhenUcBeQE-l3jWbgtaNIQ_19_6",
"capex": "d1#Tc_AD2Wj5oxmE6WT0Ks1ufkDw_22_6",
"purchase_of_intangible_assets": "d1#Tc_tn90fLXl8Ey5PQTgJB_N3w_24_6",
"investing_cash_flow": "d1#Tc_yAEaQKCb7U2n1a6vU2h39g_33_6",
"dividends_paid": "d1#Tc_e29s9Z0nP0GaDZFOKGg3rg_41_6",
"financing_cash_flow": "d1#Tc_gURAlCp78kKj-xepry5j4A_46_6",
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": "d1#Tc_KXCVwa0R-USpGoAMr-U7jw_48_4"
}
},
{
"period_end": "2023-12-31",
"income_statement": {
"product_sales": "d1#Tc_npmfGG8CwkS9Sz6EWKGwYg_3_8",
"alliance_revenue": "d1#Tc_Sq87fGl7W0Wkf3mOw1iQxg_4_8",
"product_revenue": "d1#Tc_8vnkY64OMEOWEMTkOhbJHw_5_8",
"collaboration_revenue": "d1#Tc_bAke8MMIbU6BOWu1pvKNuQ_6_8",
"total_revenue": "d1#Tc_jZJc5zNatE27u8EoLlxEGQ_7_8",
"cost_of_sales": "d1#Tc_zKqXTYDnR06sf9OyYjVw1Q_8_8",
"gross_profit": "d1#Tc_d61Zi3DhM0enhY2LlKAgqQ_9_8",
"distribution_expense": "d1#Tc__h1HgioLz0m804bZGB3hUA_10_8",
"research_and_development_expense": "d1#Tc_b6QR1yfgBE6lM6nWXoOYMw_11_8",
"selling_general_and_administrative_expense": "d1#Tc_Us_OgfMlQU-zW0YphkjB5w_12_8",
"other_operating_income_and_expense": "d1#Tc_uAlF5DZ5c0qHp6InOzyW9g_13_8",
"operating_profit": "d1#Tc_oreBwwV30kKkmcJmy4fnSg_14_8",
"finance_income": "d1#Tc_FXrXwso7QU2SKG_5pdUOlw_15_8",
"finance_expense": "d1#Tc_EmYtcIAx8Uyh5WTTrhgPBQ_16_8",
"share_of_losses_of_associates_and_joint_ventures": "d1#Tc_xXwzuVGLp0-_uzjSW7As3A_17_8",
"profit_before_tax": "d1#Tc_j_EuCwkgKUyENck7Qa4pow_18_8",
"taxation": "d1#Tc_cLgC-stiJUSyelhkKDHKBQ_19_8",
"net_income": "d1#Tc_0hbezPmOdka_igkEbQtP9g_20_8",
"net_income_attributable_to_owners_of_parent": "d1#Tc_sepDlB0EOkqmwbBovglm5Q_41_8",
"net_income_attributable_to_noncontrolling_interests": "d1#Tc_xnzwLqtfaUW4SGCGFs2n_w_42_8",
"basic_eps": "d1#Tc_z1dhbamaG0OFeqyEBWBwvA_47_8",
"diluted_eps": "d1#Tc_bCKNS800pEui8uqwlwKcVg_48_8",
"basic_shares": "d1#Tc_rvzTrBLq-0mpU9n7IYn3KQ_49_8",
"diluted_shares": "d1#Tc_k2dQtEJul0moGplaeoLoKA_50_8"
},
"cash_flow": {
"depreciation_amortisation_and_impairment": "d1#Tc_QT9NLFN5B06-eZCgtM426w_7_8",
"operating_cash_flow": "d1#Tc__flPnl09HkSSer_g42SDlw_17_8",
"acquisition_of_subsidiaries_net_of_cash_acquired": "d1#Tc_rBhJPv16k0-q4JvadGUIhQ_19_8",
"capex": "d1#Tc__CjFitaxe0C0s_rjixi0XA_22_8",
"purchase_of_intangible_assets": "d1#Tc_TtRRM1qiFESSXSoPopeVJQ_24_8",
"investing_cash_flow": "d1#Tc_hnYMMMQVFUCfXraG9oV2xg_33_8",
"dividends_paid": "d1#Tc_m7-PGbV-iEiymqwUjdbTyg_41_8",
"financing_cash_flow": "d1#Tc_uBVZfhgtl0S6lb6aLKyqEA_46_8",
"cash_and_cash_equivalents_at_end_of_period_net_of_overdrafts": "d1#Tc_iid_2ojMsEWzzCbhldFuow_48_6"
}
}
]
}
}